Xbrane Biopharma
6.01 SEK
-1.30 %
Less than 1K followers
XBRANE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Xbrane Biopharma
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 66.8 | 65.8 | 198.7 | 93.2 | 39.9 | 10.1 | 9.1 | 152.4 |
| EBITDA | -37.4 | 58.5 | -127.7 | 32.6 | -7.7 | -20.7 | -21.9 | -13.6 |
| EBIT | -37.4 | -31.7 | -217.9 | 27.7 | -7.7 | -23.5 | -24.7 | -28.2 |
| EBIT-% | -56.0 % | -48.2 % | -109.7 % | 29.7 % | -19.3 % | -232.6 % | -271.4 % | -18.5 % |
| Profit before taxes | -44.8 | -41.3 | -253.4 | 19.3 | -13.3 | -23.7 | -26.2 | -43.9 |
| Net income | -45.1 | -53.2 | -266.2 | 8.2 | 169.6 | -24.0 | -26.5 | 127.2 |